Cargando…

A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis

OBJECTIVE: The objective of this study was to identify biochemical and clinical predictors of poor response (including incomplete response and non-response) to standard treatment in autoimmune hepatitis (AIH) patients. METHODS: This study retrospectively collected clinical data from 297 patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Liu, Hui, Wang, Peng, Wang, Yuqi, Yi, Yunyun, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695339/
https://www.ncbi.nlm.nih.gov/pubmed/37942733
http://dx.doi.org/10.1097/MEG.0000000000002661
_version_ 1785153546195304448
author Wang, Xin
Liu, Hui
Wang, Peng
Wang, Yuqi
Yi, Yunyun
Li, Xin
author_facet Wang, Xin
Liu, Hui
Wang, Peng
Wang, Yuqi
Yi, Yunyun
Li, Xin
author_sort Wang, Xin
collection PubMed
description OBJECTIVE: The objective of this study was to identify biochemical and clinical predictors of poor response (including incomplete response and non-response) to standard treatment in autoimmune hepatitis (AIH) patients. METHODS: This study retrospectively collected clinical data from 297 patients who were first diagnosed with AIH in Beijing Ditan Hospital from 2010 to 2019. Finally, 149 patients were screened out. Risk factors were screened by univariate and multifactorial logistic regression. Then they were used to establish the nomogram. The ROC curve, calibration curve, decision curves analysis (DCA) and clinical impact curves (CIC) were used to evaluate the nomogram. RESULTS: 149 patients were divided into two groups: the response group (n = 120, 80%) and the poor response group (n = 29, 20%). Multivariate logistic regression analysis found that IgG > 26.5 g/L (OR: 22.016; 95% CI: 4.677–103.640) in AIH patients increased the risk. In contrast, treatment response status was better in women (OR: 0.085; 95% CI: 0.015–0.497) aged >60 years (OR: 0.159; 95% CI: 0.045–0.564) with AST > 4.49 × ULN (OR: 0.066; 95% CI: 0.009–0.494). The C index (0.853) and the calibration curve show that the nomogram is well differentiated and calibrated; the DCA and CIC indicate that the model has good clinical benefits and implications. CONCLUSION: The study found that male patients aged ≤ 60 years with IgG > 26.5 g/L and elevated AST ≤ 4.49 × ULN were more likely to have a non-response/incomplete response to standard treatment.
format Online
Article
Text
id pubmed-10695339
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams And Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106953392023-12-05 A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis Wang, Xin Liu, Hui Wang, Peng Wang, Yuqi Yi, Yunyun Li, Xin Eur J Gastroenterol Hepatol Original Articles: Hepatology OBJECTIVE: The objective of this study was to identify biochemical and clinical predictors of poor response (including incomplete response and non-response) to standard treatment in autoimmune hepatitis (AIH) patients. METHODS: This study retrospectively collected clinical data from 297 patients who were first diagnosed with AIH in Beijing Ditan Hospital from 2010 to 2019. Finally, 149 patients were screened out. Risk factors were screened by univariate and multifactorial logistic regression. Then they were used to establish the nomogram. The ROC curve, calibration curve, decision curves analysis (DCA) and clinical impact curves (CIC) were used to evaluate the nomogram. RESULTS: 149 patients were divided into two groups: the response group (n = 120, 80%) and the poor response group (n = 29, 20%). Multivariate logistic regression analysis found that IgG > 26.5 g/L (OR: 22.016; 95% CI: 4.677–103.640) in AIH patients increased the risk. In contrast, treatment response status was better in women (OR: 0.085; 95% CI: 0.015–0.497) aged >60 years (OR: 0.159; 95% CI: 0.045–0.564) with AST > 4.49 × ULN (OR: 0.066; 95% CI: 0.009–0.494). The C index (0.853) and the calibration curve show that the nomogram is well differentiated and calibrated; the DCA and CIC indicate that the model has good clinical benefits and implications. CONCLUSION: The study found that male patients aged ≤ 60 years with IgG > 26.5 g/L and elevated AST ≤ 4.49 × ULN were more likely to have a non-response/incomplete response to standard treatment. Lippincott Williams And Wilkins 2023-11-23 2024-01 /pmc/articles/PMC10695339/ /pubmed/37942733 http://dx.doi.org/10.1097/MEG.0000000000002661 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Articles: Hepatology
Wang, Xin
Liu, Hui
Wang, Peng
Wang, Yuqi
Yi, Yunyun
Li, Xin
A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis
title A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis
title_full A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis
title_fullStr A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis
title_full_unstemmed A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis
title_short A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis
title_sort nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis
topic Original Articles: Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695339/
https://www.ncbi.nlm.nih.gov/pubmed/37942733
http://dx.doi.org/10.1097/MEG.0000000000002661
work_keys_str_mv AT wangxin anomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT liuhui anomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT wangpeng anomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT wangyuqi anomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT yiyunyun anomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT lixin anomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT wangxin nomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT liuhui nomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT wangpeng nomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT wangyuqi nomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT yiyunyun nomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis
AT lixin nomogramforanalyzingriskfactorsofpoortreatmentresponseinpatientswithautoimmunehepatitis